A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: Mobilan (M-VM3)Drug: Placebo
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Panacela Labs LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02844699
- Locations
- π·πΊ
Federal State Budgetary Institution "Saint Petersburg Clinical Scientific and Practical Center for Special types of medical care (Oncological)", Saint Petersburg, Russian Federation
π·πΊMoscow State Budgetary Healthcare Institution "City Clinical Hospital β 57" of Moscow Healthcare Department, Moscow, Russian Federation
π·πΊMoscow State University of Medicine and Dentistry, Moscow, Russian Federation
Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: Mobilan (M-VM3)Drug: Placebo
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Panacela Labs LLC
- Target Recruit Count
- 32
- Registration Number
- NCT02654938
- Locations
- π·πΊ
Moscow Scientific Research Institute of Oncology named after P. A. Hertsen of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
π·πΊFederal State Budgetary Institution "Russian Oncological Research Center named after N. N. Blokhin" of the Russian Academy of Sciences, Moscow, Russian Federation
π·πΊFederal State Budgetary Institution "Saint Petersburg Clinical Scientific and Practical Center for Special types of medical care (Oncological)", Saint Petersburg, Russian Federation